{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:13:34Z","timestamp":1790612014777,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Interleukin (IL)-17A is essential for intestinal mucosal integrity, contributing to the prevention of detrimental immunity such as infectious colitis and inflammatory bowel disease (IBD). Indeed, neutralization of IL-17A has been abandoned as a therapeutic principle in IBD because of increased disease activity. However, it is controversial whether IL-17A inhibitors increase the risk of developing colitis in patients who do not have underlying IBD. Here, we present two cases of different forms of colitis that occurred during treatment with two IL-17A inhibitors, secukinumab and ixekizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentations<\/jats:title>\n                <jats:p>We report the case of a 35-year-old female with SAPHO (synovitis\u2013acne\u2013pustulosis\u2013hyperostosis\u2013osteitis) syndrome who was admitted due to severe colitis with bloody diarrhea, fever, abdominal pain and weight loss after receiving secukinumab for 3\u00a0months as well as the case of a 41-year-old male with psoriatic arthritis who presented himself to the outpatient clinic with bloody stools, abdominal pain and nausea 5\u00a0months after changing his therapy from secukinumab to ixekizumab. In both patients, treatment with IL-17A-inhibitors was stopped and tumor necrosis factor inhibitors were started. Both patients recovered, are clinically stable and show no more signs of active colitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The role of IL-17A inhibitors in the pathogenesis of infectious colitis and new-onset IBD is not fully understood and requires further research. Patients receiving IL-17A-inhibitor therapy should be carefully screened and notified of the possible side effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12328-023-01893-9","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T06:02:07Z","timestamp":1701928927000},"page":"263-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Colitis induced by IL-17A-inhibitors"],"prefix":"10.1007","volume":"17","author":[{"given":"Lea","family":"Gr\u00fcmme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kn\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Skapenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"1893_CR1","doi-asserted-by":"publisher","first-page":"928461","DOI":"10.1155\/2014\/928461","volume":"2014","author":"J G\u00e1lvez","year":"2014","unstructured":"G\u00e1lvez J. Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014;2014:928461.","journal-title":"ISRN Inflamm"},{"issue":"9","key":"1893_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585\u2013600.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1893_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","volume":"129","author":"RM Onishi","year":"2010","unstructured":"Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311\u201321.","journal-title":"Immunology"},{"issue":"4","key":"1893_CR4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892\u2013906.","journal-title":"Immunity"},{"issue":"1","key":"1893_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","volume":"30","author":"H Ishigame","year":"2009","unstructured":"Ishigame H, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30(1):108\u201319.","journal-title":"Immunity"},{"key":"1893_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-94-017-9487-9_5","volume":"841","author":"X Song","year":"2014","unstructured":"Song X, Gao H, Qian Y. Th17 Differentiation and their pro-inflammation function. Adv Exp Med Biol. 2014;841:99\u2013151.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"1893_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","volume":"79","author":"M Fauny","year":"2020","unstructured":"Fauny M, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1893_CR8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"key":"1893_CR9","first-page":"9679287","volume":"2018","author":"D Ehrlich","year":"2018","unstructured":"Ehrlich D, et al. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Rep Gastrointest Med. 2018;2018:9679287.","journal-title":"Case Rep Gastrointest Med"},{"key":"1893_CR10","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.14309\/crj.2018.56","volume":"5","author":"J Wang","year":"2018","unstructured":"Wang J, et al. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Rep J. 2018;5:e56.","journal-title":"ACG Case Rep J"},{"key":"1893_CR11","doi-asserted-by":"crossref","unstructured":"Fieldhouse KA, et al., Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context. 2020;9","DOI":"10.7573\/dic.2020-2-1"},{"issue":"6","key":"1893_CR12","doi-asserted-by":"publisher","first-page":"e15151","DOI":"10.1111\/dth.15151","volume":"34","author":"AK Ali","year":"2021","unstructured":"Ali AK, et al. New onset inflammatory bowel disease in patient treated with secukinumab: case report and review of literature. Dermatol Ther. 2021;34(6):e15151.","journal-title":"Dermatol Ther"},{"key":"1893_CR13","first-page":"2975631","volume":"2019","author":"TG Achufusi","year":"2019","unstructured":"Achufusi TG, Harnee PS, Rawlins S. A rare case of new-onset ulcerative colitis following initiation of secukinumab. Case Rep Med. 2019;2019:2975631.","journal-title":"Case Rep Med"},{"issue":"6","key":"1893_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S0190-9622(09)80081-9","volume":"31","author":"M Malmusi","year":"1994","unstructured":"Malmusi M, Manca V, Girolomoni G. Coexistence of dermatitis herpetiformis, gluten-sensitive enteropathy, and ulcerative colitis. J Am Acad Dermatol. 1994;31(6):1050\u20131.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1893_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/cpt.2155","volume":"110","author":"N Petitpain","year":"2021","unstructured":"Petitpain N, et al. IL-17 inhibitors and inflammatory bowel diseases: a postmarketing study in vigibase. Clin Pharmacol Ther. 2021;110(1):159\u201368.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1893_CR16","doi-asserted-by":"publisher","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","volume":"72","author":"DD Patel","year":"2013","unstructured":"Patel DD, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(2):ii116\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1893_CR17","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978.","journal-title":"Ann Rheum Dis"},{"key":"1893_CR18","unstructured":"Leipe JHD, Meier J, Witt M, Grunke M, Dechant C, Schulze-Koops H, Clinical features in CRMO patients with mandible manifestation\u2014a cohort study. 2016."},{"issue":"6","key":"1893_CR19","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1111\/j.1572-0241.2001.03896.x","volume":"96","author":"ES Bonapace","year":"2001","unstructured":"Bonapace ES, Srinivasan R. Simultaneous occurrence of inflammatory bowel disease and thyroid disease. Am J Gastroenterol. 2001;96(6):1925\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"1893_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.4065\/75.8.802","volume":"75","author":"K Kimura","year":"2000","unstructured":"Kimura K, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc. 2000;75(8):802\u20136.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1893_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clindermatol.2007.08.006","volume":"25","author":"E Christophers","year":"2007","unstructured":"Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529\u201334.","journal-title":"Clin Dermatol"},{"issue":"8","key":"1893_CR22","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1007\/s10620-013-2653-6","volume":"58","author":"JE Naves","year":"2013","unstructured":"Naves JE, et al. A systematic review of SAPHO syndrome and inflammatory bowel disease association. Dig Dis Sci. 2013;58(8):2138\u201347.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1893_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/art.24540","volume":"61","author":"M Colina","year":"2009","unstructured":"Colina M, et al. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum. 2009;61(6):813\u201321.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1893_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0049-0172(99)80027-4","volume":"29","author":"G Hayem","year":"1999","unstructured":"Hayem G, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum. 1999;29(3):159\u201371.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1893_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/art.41923","volume":"74","author":"L Penso","year":"2022","unstructured":"Penso L, et al. Risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis\/ankylosing spondylitis initiating interleukin-17 inhibitors: a nationwide population-based study using the French national health data system. Arthritis Rheumatol. 2022;74(2):244\u201352.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1893_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1874467210801010068","volume":"1","author":"SC Tauber","year":"2008","unstructured":"Tauber SC, Nau R. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol. 2008;1(1):68\u201379.","journal-title":"Curr Mol Pharmacol"},{"key":"1893_CR27","doi-asserted-by":"crossref","unstructured":"Sauer A, et al., Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment. Eur Respir Rev, 2021;30(162).","DOI":"10.1183\/16000617.0093-2021"},{"issue":"1","key":"1893_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13054-022-03909-1","volume":"26","author":"A Sauer","year":"2022","unstructured":"Sauer A, Putensen C, Bode C. Immunomodulation by tetracyclines in the critically Ill: an emerging treatment option? Crit Care. 2022;26(1):74.","journal-title":"Crit Care"},{"issue":"2","key":"1893_CR29","doi-asserted-by":"publisher","first-page":"e1463897","DOI":"10.1080\/21688370.2018.1463897","volume":"6","author":"AN Anbazhagan","year":"2018","unstructured":"Anbazhagan AN, et al. Pathophysiology of IBD associated diarrhea. Tissue Barriers. 2018;6(2):e1463897.","journal-title":"Tissue Barriers"},{"key":"1893_CR30","doi-asserted-by":"crossref","unstructured":"Azevedo A, Torres T, The successful treatment with ixekizumab in a multi-failure psoriasis patient. Dermatol Online J, 2018;24(9).","DOI":"10.5070\/D3249041420"},{"issue":"1","key":"1893_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaad.2018.01.003","volume":"79","author":"JR Georgakopoulos","year":"2018","unstructured":"Georgakopoulos JR, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol. 2018;79(1):155\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1893_CR32","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bjd.16497","volume":"178","author":"C Paul","year":"2018","unstructured":"Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178(5):1003\u20135.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1893_CR33","doi-asserted-by":"publisher","first-page":"e13313","DOI":"10.1111\/dth.13313","volume":"33","author":"E Herrera-Acosta","year":"2020","unstructured":"Herrera-Acosta E, et al. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: real-world practice. Dermatol Ther. 2020;33(3):e13313.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1893_CR34","doi-asserted-by":"publisher","first-page":"8906","DOI":"10.1038\/s41598-017-08360-9","volume":"7","author":"A Goepfert","year":"2017","unstructured":"Goepfert A, et al. The human IL-17A\/F heterodimer: a two-faced cytokine with unique receptor recognition properties. Sci Rep. 2017;7(1):8906.","journal-title":"Sci Rep"},{"key":"1893_CR35","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng Z, et al. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front Pharmacol. 2023;14:1124628.","journal-title":"Front Pharmacol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01893-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-023-01893-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01893-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T13:15:38Z","timestamp":1711199738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-023-01893-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1007\/s12328-023-01893-9","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Ethical approval was waived by the local Ethics Committee of the Hospital of the Ludwig Maximilians University of Munich in view of the retrospective nature of the study (22-0983 KB) and all the procedures being performed were part of the routine care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}